3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
11.78
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/25 Issuer sale

Director

1,553,657 5.8540%
7/17/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
7/17/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--% - - 106M
+0.12%+0.98%+26.39%+37.32% 245B
+0.74%+3.35%+8.63%+6.40% 156B
-1.30%+4.27%-3.14%+54.52% 151B
-1.21%+2.65%-54.39%-12.54% 63.53B
-1.30%-1.40%+16.89%+20.47% 49.8B
+0.73%+4.86%-15.64%-15.99% 49.28B
+0.16%+1.34%+24.14%+55.28% 48.3B
+1.95%+6.40%+5.43%+39.57% 47.9B
-0.68%-1.66%+27.60%+69.89% 42.45B
Average +0.30%+1.82%+3.99%+28.32% 94.74B
Weighted average by Cap. -0.10%+1.54%+7.67%+29.71%
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock